Live feed07:00:00·232dPRReleasevia QuantisnowCaribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell TherapiesByQuantisnow·Wall Street's wire, on your screen.CRBU· Caribou Biosciences Inc.Health Care
